It appears you have not yet Signed Up with our community. To Sign Up for free, please click here....



Multiple Sclerosis Message Board
Post New Thread   Closed Thread
LinkBack Thread Tools
Old 04-01-2005, 10:07 PM   #1
Senior Member
(female)
 
Join Date: Mar 2005
Posts: 167
Moon Rising HB User
Exclamation NeuroVax- Quarterly Drug

Vaccine for multiple sclerosis, NeuroVax™ is an immune-based therapy designed to specifically down-regulate the body’s destructive immune responses observed in MS patients to alleviate the impact of the disease.

“The NeuroVax™ data we’ve seen thus far lead us to believe that it may have a clinical benefit for MS patients and we are excited to begin this new Phase II study to provide additional important information about the therapy’s mechanism-of-action and long-term safety,” said John N. Bonfiglio, Ph.D., President and Chief Executive Officer of The Immune Response Corporation.

Last year, the Company presented data demonstrating that NeuroVax™ produced a peptide-specific immune response in 94 percent of the patients treated in a Phase I/II clinical trial in MS. A separate open-label rollover study has now completed enrollment and is currently following those patients to evaluate the long-term safety of NeuroVax™. The new Phase II study announced today will build on the knowledge acquired in these studies and seek to further understand the mechanism-of-action of NeuroVax™ and explore possible dosing regimens.

“This new Phase II study is designed to examine the durability of the immunological responses we’ve seen in patients receiving NeuroVax™,” said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. “We may be able to successfully maintain these responses with a quarterly dosing regimen which would be an important benefit to patients.”

The new open-label study will ultimately enroll 40 patients with relapsing remitting or secondary progressive multiple sclerosis, of which approximately 30 will be rollover patients from a previous study. Patients in this new study will receive three monthly NeuroVax™ injections followed by three quarterly injections. Enrollment is expected to be completed by spring 2005 and results are expected in 2006.

The Company’s strategy for the development of NeuroVax™ includes not only the expansion and completion of the current and new Phase II trials, but also the initiation in summer 2005 of a large placebo controlled trial designed with magnetic resonance imaging (MRI) and clinical endpoints to examine the clinical benefit of NeuroVax™. The Company also intends to search for a corporate partner to help take this program to commercialization

 
Sponsors Lightbulb
   
Closed Thread

Similar Threads
Thread Thread Starter Board Replies Last Post
N E U R O V A X Piano Man Multiple Sclerosis 5 12-11-2007 03:16 PM




Thread Tools

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is Off
HTML code is Off
Trackbacks are Off
Pingbacks are Off
Refbacks are Off




Join Our Newsletter

Stay healthy through tips curated by our health experts.

Whoops,

There was a problem adding your email Try again

Thank You

Your email has been added








TOP THANKED CONTRIBUTORS



MSJayhawk (937), MSNik (497), Snoopy61 (55), Whimpurr (13), J-one (13), shahila (12), JodiH (11), MS22 (11), Canadian gal (10), KingBaxter (10)

Site Wide Totals

teteri66 (1136), MSJayhawk (941), Apollo123 (855), janewhite1 (823), Titchou (769), Gabriel (743), ladybud (667), sammy64 (666), midwest1 (654), BlueSkies14 (610)



All times are GMT -7. The time now is 08:12 AM.



Site owned and operated by HealthBoards.com™
Copyright and Terms of Use © 1998-2014 HealthBoards.com™ All rights reserved.
Do not copy or redistribute in any form!